This assumption has been further confirmed showing that, under treatment with second-generation ALK inhibitors, NSCLC cells activated the EGFR family pathways directly through the NRG1-ErbB3-EGFR activation axis [25]. This evidence concerns the gene ALK and non-small cell lung carcinoma.